Monte Rosa Therapeutics, Inc. - COMMON STOCK (GLUE)

Historical Holders from Q2 2021 to Q3 2025

Symbol
GLUE on Nasdaq
Type / Class
Equity / COMMON STOCK
Shares outstanding
61,827,467
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
60,027,627
Holdings value
$444,802,878
% of all portfolios
0%
Number of holders
126
Number of buys
58
Number of sells
-55
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Monte Rosa Therapeutics, Inc. - COMMON STOCK (GLUE)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BIOTECHNOLOGY VALUE FUND L P 9.2% +28.6% $29,545,889 +$6,613,333 5,660,132 +28.8% BVF PARTNERS L P/IL 31 Mar 2025
Dimension Capital I, L.P. 7.7% $22,979,029 4,757,563 Adam Goulburn 16 May 2024
PRICE T ROWE ASSOCIATES INC /MD/ 7.5% $34,360,615 4,637,060 T. Rowe Price Associates, Inc. 30 Sep 2025
TCG Crossover GP II, LLC 7.2% $32,812,836 4,427,705 Chen Yu 10 Oct 2025
BlackRock, Inc. 6.3% $20,045,661 3,840,165 BlackRock, Inc. 31 Dec 2024
SUVRETTA CAPITAL MANAGEMENT, LLC 5.5% $17,539,200 3,360,000 SUVRETTA CAPITAL MANAGEMENT, LLC 09 Apr 2025
Versant Venture Capital VI, L.P. 5.1% $24,709,897 3,334,669 Versant Venture Capital VI, L.P. 10 Nov 2025
VANGUARD GROUP INC 4.83% -6% $22,148,142 -$1,240,441 2,988,953 -5.3% The Vanguard Group 30 Sep 2025
FMR LLC 2.8% $7,072,953 1,750,731 FMR LLC 30 May 2025

Institutional Holders of Monte Rosa Therapeutics, Inc. - COMMON STOCK (GLUE)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 60,027,627 $444,802,878 -$4,386,129 $7.41 126
2025 Q2 62,196,889 $280,514,086 +$11,963,150 $4.51 115
2025 Q1 59,523,717 $276,191,314 -$11,913,266 $4.64 105
2024 Q4 60,988,332 $423,262,031 +$79,110,231 $6.94 104
2024 Q3 49,754,753 $263,674,421 +$18,158,687 $5.3 80
2024 Q2 45,836,316 $171,427,053 +$21,976,071 $3.74 73
2024 Q1 39,892,581 $281,249,822 -$731,896 $7.05 67
2023 Q4 40,102,427 $226,575,690 -$10,023,054 $5.65 71
2023 Q3 42,042,126 $201,382,486 +$10,940,133 $4.79 70
2023 Q2 39,734,743 $272,184,520 -$3,199,539 $6.85 67
2023 Q1 39,769,032 $309,801,540 -$11,077,618 $7.79 69
2022 Q4 41,325,746 $314,458,629 +$7,213,706 $7.61 66
2022 Q3 40,353,101 $329,604,037 -$3,246,200 $8.17 70
2022 Q2 38,778,221 $374,994,819 -$11,927,308 $9.67 56
2022 Q1 39,943,480 $559,876,587 +$42,034,475 $14.02 52
2021 Q4 36,340,047 $741,974,000 +$28,074,571 $20.42 53
2021 Q3 34,892,057 $759,420,127 +$60,728,601 $22.28 54
2021 Q2 32,095,195 $705,074,000 +$705,074,000 $22.7 48